Enixum, 4000 anti-ha me/0.4ml 0.4 ml 10 pcs
€1.00
Out of stock
(E-mail when Stock is available)
- Prevention of venous thrombosis and embolism in surgical interventions, especially in orthopedic and general surgical procedures;
- prevention of venous thrombosis and embolism in patients on bed rest due to acute therapeutic diseases, including acute heart failure and decompensation of chronic heart failure. Prevention of venous thrombosis and embolism in bedridden patients due to acute medical conditions, including acute heart failure and decompensation of chronic heart failure (NYHA class III or IV), acute respiratory failure; acute infectious diseases; acute stages of rheumatic diseases combined with a risk factor for venous thrombosis (see “Special Instructions. “
- treatment of deep vein thrombosis with or without pulmonary embolism;
- prevention of thrombosis in the extracorporeal circulation system during hemodialysis (usually with a session duration of 4 hours or less);
- treatment of unstable angina and myocardial infarction without Q-wave in combination with acetylsalicylic acid;
- treatment of acute ST-segment elevation myocardial infarction in patients undergoing drug treatment or subsequent percutaneous coronary intervention.
Active ingredient
Enoxaparin sodium
Composition
1 syringe (0.4 ml) contains as active ingredient Enoxaparin sodium 4000 anti-Ha IU (40 mg);
How to take, the dosage
Enixum® is administered subcutaneously (deeply), in special cases (see below) into the arterial circuit during a hemodialysis session and intravenously.
Interaction
Do not mix Enixum® with other medicines in the same syringe.
Special Instructions
When prescribing the drug for prophylactic purposes, no tendency to increased bleeding has been revealed. When prescribing the drug for therapeutic purposes, there is a risk of bleeding in elderly patients (especially over 80 years). Close monitoring of the patient’s condition is recommended.
Contraindications
- Ensensitivity to enoxaparin sodium, heparin or its derivatives, including other low molecular weight heparins;
- circumstances and diseases with a high risk of bleeding: threatened abortion, cerebral vascular aneurysm, or dissecting aortic aneurysm (except for surgery);
- hemorrhagic stroke;
- uncontrollable bleeding;
- not recommended for use in pregnant women with artificial heart valves;
- age below 18 years of age (efficacy and safety not established).
With caution
- disorders of hemostasis (including hemophilia, thrombocytopenia, hypocoagulation, Willebrand disease, etc.), severe vasculitis;
- Gastric or duodenal ulcer or other gastrointestinal erosive and ulcerative lesions;
- Last ischemic stroke;
- diabetic or hemorrhagic retinopathy;
- severe diabetes mellitus;
- late or suspected neurologic or ophthalmic surgery;
- spinal or epidural anesthesia (potential risk of hematoma), spinal tap (recent);
- future delivery;
- bacterial endocarditis (acute or subacute);
- pericarditis or pericardial effusion;
- intrauterine contraception (IUD);
- severe trauma (especially central nervous system (CNS)), open wounds on large surfaces;
- concurrent administration of drugs that affect the hemostatic system.
There are no data on the clinical use of the drug in the following diseases: active tuberculosis, radiation therapy (recently taken).
Side effects
WHO classification of adverse drug reactions by frequency of occurrence:
Overdose
Symptoms: hemorrhagic complications of accidental overdose during subcutaneous injection of enoxaparin sodium. Absorption of the drug is unlikely when administered orally, even in large doses.
Similarities
Clexane
Weight | 0.177 kg |
---|---|
Shelf life | 2 years. |
Conditions of storage | At a temperature not exceeding 25 ° C. Do not freeze. Keep out of reach of children. |
Manufacturer | PharmFirm Sotex, Russia |
Medication form | solution for injection |
Brand | PharmFirm Sotex |
Other forms…
Related products
Buy Enixum, 4000 anti-ha me/0.4ml 0.4 ml 10 pcs with delivery to USA, UK, Europe and over 120 other countries.